![drinking_water_swallowing_dysphagia](https://pharmaphorum.com/wp-content/uploads/2022/10/drinking_water_swallowing_dysphagia.jpg)
Weak data for Fasenra undermine AZ's ambitions for the drug
AstraZeneca's IL-5 inhibitor Fasenra is already making blockbuster sales from its use in eosinophilic asthma, but the drugmaker's efforts to expand its label keep running into difficulties.